Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2025
Hepatic antifibrotic effects of bezafibrate in vitro and in vivo models of liver fibrosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reghelin Camille Kirinus, Bastos Matheus Scherer, de Souza Basso Bruno, Costa Bruna Pasqualotto, Cruz de Sousa Arieli, Martha Bianca Andrade, Antunes Géssica Luana, Nassr Marcella Tornquist, Rosa Garcia Maria Claudia, Matzenbacher Lucas Strassburger, Schneider Levorse Vitor Giancarlo, Costa Rodrigues Guma Fatima Theresinha, Donadio Márcio Vinícius Fagundes, Rodrigues de Oliveira Jarbas, Alberto da Silva Melo Denizar
Аннотация
Bezafibrate (BZF) is a drug that reduces cholesterol and triglyceride levels in the blood. Research indicates that BZF, through activation of PPAR receptors, regulates the expression of genes involved in lipid homeostasis, inflammation, cell differentiation, and proliferation. This study investigated the in vitro and in vivo effects of BZF on activated hepatic stellate cells (HSCs) and on carbon tetrachloride-induced liver fibrosis in mice. After 72 h of treatment in vitro, BZF decreased cell proliferation, reversed the phenotype, decreased cell contraction, and induced autophagy. In addition, BZF promoted a protective effect on tetrachloride-induced liver fibrosis in mice, through antifibrotic actions. These findings suggest that BZF may have a potential antifibrotic effect, which could emerge as a possible new therapy for the treatment of liver fibrosis.